Open AccessDevelopment and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome
Author(s) -
Liseth de Wolff,
Suzanne Arends,
Elena Pontarini,
Michèle Bombardieri,
Simon Bowman,
Hendrika Bootsma
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/i8g5nd
Subject(s) - medicine , abatacept , rituximab , clinical endpoint , clinical trial , placebo , rheumatoid arthritis , physical therapy , lymphoma , pathology , alternative medicine
To develop and evaluate the Clinical Trials EULAR Sjögren's Syndrome Disease Activity Index (ClinTrialsESSDAI), consisting of frequently active clinical domains of the ESSDAI, using two randomised controlled trials in primary Sjögren's syndrome (pSS).